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Abstract
Uraemia is a state of elevated plasma urea well related to a low cognitive profile. Although renal transplantation has been proved to improve cognition in these 
patients, little is known about how haemodialysis act on this scenario. Here we aimed to conduct a pilot study to fathom the presence and magnitude of a possible 
benefit of haemodialysis in cognition. Our main instrument was the Montreal Cognitive Assessment (MoCA) test, a tool designed to allow for a sensitive score for 
cognitive impairment. Although preliminary, our data were significant (p=0.012) to suggest that haemodialysis might be an important tool for cognitive improvement 
of end-stage kidney disease patients, tough not sufficient for a full cognitive recovery. 
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Introduction 
Uraemia or uraemic syndrome is a state caused by elevated 
plasma urea, usually accompanied by other nitrogen compounds 
elevation, molecules commonly excreted through the kidneys. It’s a 
more limited term than azotaemia, since uraemia generally refers to 
high plasmatic urea causing a certain degree of symptomatology due 
to kidney dysfunction, while azotaemia is a laboratorial indication of 
elevated plasma urea that can also imply pre- and post-renal defects, 
such as reduced renal blood flow and obstruction of urine flow, 
respectively [1]. Although we intent to use the narrow definition, both 
terms indicate the same organic contingency for our purposes, one in 
which the cognition might be impaired due to nitrogen compounds’ 
neurotoxicity.
It is estimated that between 30 and 70% of chronic kidney disease 
patients have some degree of cognitive issues [2]; however, the precise 
relation between uraemia and cognitive impairment is still unknown. 
Asymmetric dimethylarginine and guanidine-related compounds are 
proposed neurotoxins involved in cognitive deterioration due to renal 
failure and uraemic encephalopathy. The CNS might also be damaged 
during renal failure by secondary hyperparathyroidism, which affects 
cytosolic calcium levels within synaptosomes, GABA content in the 
brain, and noradrenaline and acetylcholine metabolism [3,4]. The 
relationship between uraemia and cognitive decline is strengthened 
by the already described cognitive improvement in dialytic patients 
after renal transplantation [5,6]. The literature is well served of studies 
comparing cognition and CNS parameters of patients undergoing 
dialysis and healthy baseline parameters [3]. Nonetheless, to the best of 
our knowledge, no study has evaluated cognitive performance before 
and after haemodialysis starts in the same group of patients.
The Montreal Cognitive Assessment (MoCA) test was our tool for 
analysing cognitive performance. It consists of 30 questions that must 
be solved using drawing, careful listening, and intellectual and simple 
mathematical skills; each question accounts for one point, being thus 
the maximum score 30. MoCA is a relatively new test which is being 
increasingly used for cognitive impairment assessment, due to its high 
sensitivity and test-retest reliability [7] and concordance with standard 
neuropsychological tests [8]. 
The Geriatric Depression Scale with 15 questions (GDS-15) is a yes-
no questionnaire that provides a quick alternative to the psychiatric 
interview when screening for depression, especially in older people. A 
work comparing GDS-15 to the Beck’s Depression Inventory (BDI) – 
an already validated tool for depression assessment – in the context of 
haemodialytic patients has shown that GDS-15 has a high predictive 
accuracy versus the BDI and even a psychiatric interview, which is the 
gold-standard [9]. The cut-off value with best diagnostic accuracy in 




Patients were randomly chosen from the Hospital de Clínicas de 
Porto Alegre (HCPA) end-stage uraemia outpatient ambulatory’s list 
and explained the purposes of the study. Including criteria were 1) 
having end-stage chronic kidney disease (that is, having a glomerular 
filtration ratio (GFR) equal or lower to 15 ml/min/1.73m²) and 2) 
having plans to start dialysis within one year. The sole exclusion 
criterion was having any neurological or any psychiatric disorder 
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other than depression. All patients explicitly agreed in participating at 
the study after being thoroughly explained about it, according to the 
Declaration of Helsinki and the HCPA Ethical Committee. A total of 
17 patients were enrolled. 
Regarding the experiment’s control, we designed the study so that 
the patients are their own controls, since a separate group would be 
inevitably biased: healthy participants matching age and school years 
would always tend to score better, and participants with chronic kidney 
disease with no dialysis plan would tend to score worse in the second 
testing, due to disease progress in the meantime, thus biasing the results. 
Besides, comparing the patients to themselves has the advantage of 
giving a better view of the treatment’s pure effect instead of mixing in 
the analysis the patients’ different sociocultural backgrounds. 
Cognitive testing
For cognitive testing, we used the Montreal Cognitive Assessment 
test (MoCA test) in its Brazilian version (MoCA-BR) made in 2007 
by Bertolucci, Sarmento and Wajman [10] and validated in 2013 by 
Memória and colleagues [11]. MoCA-BR shows a sensibility of 81% 
and a specificity of 77% for mild cognitive impairment, [8] thus being 
more suited as a screening test than the Mini-Mental State Examination 
(MMSE), the most commonly used tool, which has the same sensitivity, 
but a much lower specificity (81% and 65%, respectively) determined 
for a population with similar characteristics than ours [12]. All tests 
were applied by the authors, having all received the same training by 
a neurogeriatrician (the last author). We used MoCA test results as 
a non-parametric variable, since all but one patient scored under the 
commonly used cut-off value of 23 points at the first evaluation. 
Depressive symptomatology
To control for a possible confounder, we made a quick screening 
for depression using the Geriatric Depression Scale in its 15-question 
format (GDS-15), validated to Brazilian Portuguese [13]. We chose to 
use GDS-15 for depression screening due to the high sensibility and 
sensitivity of this scale (up to 87% and 82%, respectively) [10] and the 
little time it takes to be applied (less than five minutes). Patients scoring 
more than 5 points are considered to be of high risk for depression, and 
those scoring 5 or less to be of low risk.
Statistics
All the patients’ data was kept in a Microsoft Excel data bank 
(Microsoft Inc, v15.0). Statistical analyses were made using SPSS (IBM, 
v18.0) with the help of a statistician from HCPA. For the comparison 
between paired, non-parametric samples (MoCA and GDS-15 scores 
before and during haemodialysis), Wilcoxon signed-ranks test was 
performed. For comparison between independent, non-parametric 
samples, Mann-Whitney U test was performed.  
Results
Altogether, only 10 out of 17 patients started haemodialysis in 1.5 
years, further reducing the sample size; of the 7 patients that did not 
enter the treatment, two were transplanted before dialysis began, and 
the other five decided to postpone it while clinical treatments could still 
be made. Median age of the patients that entered haemodialysis at the 
first testing was of 60.5 years, ranging from 33 to 66 years (SD=13.3). 
Median school years of patients that entered haemodialysis was of 7.5 
years, ranging from 1 to 12 years (SD=4.12); all the patients received 
one extra point in their MoCA test final scores as an adaptation for low 
study years, as described in the score. Since the patients were compared 
with themselves, adjustment for age was not necessary. 
MoCA test 
The MoCA test results of the ten patients that did enter dialysis was 
of 17.5 ± 4.2 and 19.5 ± 3.5 (median ± SD) before treatment start and 
during treatment, respectively (p=0.081, Wilcoxon test). The calculated 
power of the association was of 25% considering a steady difference 
of 2.0 points, which allowed us to calculate the sample size for 80% 
power to be of 24 patients (48 measurements). Since approximately 
40% of the originally tested patients did not enter haemodialysis at all 
during study time, we could conclude that a reasonable initial sample 
size for this study should be of at least 34 subjects (40% over 24); in the 
study that will be made from the information obtained in this pilot, 
this calculation will be considered. The MoCA score of the patients 
that did not enter haemodialysis resulted in a median of 18.0 ± 4.3, not 
being significantly different from the ones that did enter dialysis later 
(p=0.601, Mann-Whitney U test); this lack of difference helps to assure 
that no selection bias occurred. 
We also performed an analysis excluding the only patient who was 
permanently (pre-and post dialysis) screened with major depression 
through GDS. This patient differed from the others in that the 
difference between his test during dialysis to the one before dialysis was 
of -5, while the median of the other patients was of 3.5 with a 3.3 SD. 
The new medians of before and during treatment testing were of 17.0 
± 4.1 and 20.0 ± 3.5, respectively, and the Wilcoxon test then yielded a 
significant p-value of 0.012.
GDS-15 results
The GDS-15 values did not change significantly from testing before 
to during haemodialysis (p>0.05, Wilcoxon test), being 4 ± 2.7 and 3 ± 
2.7, respectively. Three patients had scores higher than 5 before dialysis 
and three during dialysis. There was also no difference between the 
GDS-15 scores of patients that entered haemodialysis and those that 
did not (p>0.05, Mann-Whitney test).
Due to low sample size, it was not possible to calculate whether 
GDS-15 values correlated in any way with the MoCA test results; 
however, in a scattering plot (data not shown), a simple visual analysis 
seems to show no correlation. This question will be better addressed in 
the study that will result from the learnings obtained in this pilot. 
Discussion
Even though this is a pilot study, our data suggests that haemodialysis 
might be an important tool for cognitive improvement in patients with 
end-stage kidney disease. Although this might seem quite an intuitive 
statement, current data in the literature doesn’t support it, mostly 
because the available studies paired their data to healthy patterns and 
do not measure cognitive parameters before dialysis is initiated as a 
treatment to match this information with the cognitive evaluation after 
dialysis [3]. However, their negative results while associating dialysis 
and cognition might have a meaning if merged with our findings. 
If both data are right, we might conclude that haemodialysis is a 
favourable resource for cognitive progress in patients with end-stage 
kidney disease, but not enough for a full cognitive recovery, since a 
measurable impairment still exists. 
Regarding possible limitations in our methodology, we would 
like to address four reasonable ones. First, for technical reasons, we 
didn’t have a precise assessment of the uraemic state of each patient 
at the time of each evaluation. Our parameter was their classification 
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as pre-dialytic patients, performed by specialists based on laboratorial 
and clinical judgement at the outpatient ambulatory. Second, for 
logistic limitations of small and medium range travelling, we were 
not able to immediately evaluate the patients after they began the 
dialytic treatment, in a way that we do not have a fixed time span 
from the beginning of dialysis and the second cognitive assessment. 
Yet, all follow-ups ranged from one to six months after the onset of 
the treatment and it did not seem to interfere in our results. Third, our 
sample is a quite small one, which limited the significance and power 
of our results: based on these results, we have calculated a sample of 34 
individuals as a minimum point and presume to be able to reach this 
value in a foreseeable future in order to present a still stronger result. 
Finally, we didn’t have a control group, which would give us a more 
accurate indication that our results didn’t come from any interference 
or are part from the natural history of disease; since the main causes of 
chronic kidney disease, namely diabetes and hypertension, can cause 
per se some cognitive decline [14]. We may speculate that the effect of 
haemodialysis onto cognition could be even stronger. 
As for the study’s strengths, we would like to highlight the use of a 
sensitive clinical scale for cognitive outcomes, which possibly mimics 
reliably the patient’s and the patient’s family and friends experience 
with the cognitive decline – even though there are more sensitive 
methods to measure cognitive outcomes, their specificity to clinically 
significant findings tends to be lower, thus serving more as academic 
than practical means. We would observe as well the broad inclusion 
criteria, which suit a pilot study’s objective of determining the general 
profile of a condition to better investigate it later. 
Conclusion
Despite the small number of participants, this study preliminarily 
indicates that haemodialysis is an effective therapy for the cognitive 
decline caused by chronic kidney disease’s uraemic syndrome, at least 
in non-depressed patients. Currently, we are starting a larger, more 
controlled study to test the validity of our results, and hope to soon be 
able shed a brighter light in the subject. 
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